Orthofix Medical Inc.
NASDAQ:OFIX · NASDAQ Global Select
+$0.03 today
Vol 0.44M · Avg 0.38M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-20.5%
avg -8.1%
ROIC
-10.0%
avg -2.9%
ROA
-10.8%
avg -4.9%
Analysis
ROIC is currently the strongest return metric at -10.0% versus its period average of -2.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Massimo Calafiore | President, Chief Executive Officer & Director | $1.31M | — | 54 | $320,136.00 | 0.79% |
Lucas S. Vitale | Chief People & Business Operations Officer | $875,768.00 | — | 50 | $160,449.00 | 0.40% |
J. Andres Cedron | Chief Legal Officer & Corporate Secretary | $857,955.00 | — | 45 | $59,006.00 | 0.15% |
Patrick Fisher | President of Global Biologics & Limb Reconstruction | $796,911.00 | — | 52 | $50,633.00 | 0.13% |
Julie Andrews | Chief Financial Officer | $667,835.00 | — | 55 | $88,746.00 | 0.22% |
Aviva McPherron | President of Global Operations & Quality | $611,909.00 | — | 49 | $67,853.00 | 0.17% |
Geoffrey C. Gillespie | Chief Accounting Officer | $536,789.00 | — | — | $42,445.00 | 0.11% |
Beau Standish | Chief Enabling Technologies Officer | — | — | 46 | — | — |
Jill Mason | Chief Compliance & Risk Officer | — | — | — | $159,899.00 | 0.40% |
Julie D. Dewey | Chief Investor Relations & Communications Officer | — | — | 65 | $88,746.00 | 0.22% |
Stephanie Walsh | Chief Human Resources Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
18
$6.69M
Sells
20
$858,982.88
Net Sentiment
+$5.84M
Net buying
Most Active
Engine Capital Management, LP
13 transactions
1–10 of 38
Analysis
Insiders reported 18 buys worth $6.69M and 20 sells worth $858,982.88 over the last 12 months. That adds up to net buying of $5.84M. Engine Capital Management, LP was the most active insider with 13 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A0 analysts |
| Revenue | N/A | N/A | -5.0% | +6.8% (15yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | -53.0% | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at -5.0% over three years. Forward estimates point to Revenue at +6.8% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Butterfly Network, Inc.
NYSE:BFLY
$1.97B
MoonLake Immunotherapeutics
NASDAQ:MLTX
$1.42B
Avanos Medical, Inc.
NYSE:AVNS
$1.17B
Absci Corporation
NASDAQ:ABSI
$1.13B
SI-BONE, Inc.
NASDAQ:SIBN
$702.27M
Esperion Therapeutics, Inc.
NASDAQ:ESPR
$658.03M
Varex Imaging Corporation
NASDAQ:VREX
$445.14M
Pacific Biosciences of California, Inc.
NASDAQ:PACB
$434.84M
Standard BioTools Inc.
NASDAQ:LAB
$327.71M
DarioHealth Corp.
NASDAQ:DRIO
$50.46M
Who manages OFIX?
Orthofix Medical Inc. (OFIX) lists 11 active executives. The top listed executive is Aviva McPherron, President of Global Operations & Quality.
Are OFIX insiders buying or selling?
Recent insider activity shows net buying of $26.32M.
Explore More
Continue the stock analysis
Jump to another research area for this company.